Shares of Agile Therapeutics Inc (NASDAQ:AGRX) have been given an average rating of “Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $4.00.
A number of research analysts recently issued reports on AGRX shares. HC Wainwright set a $4.00 target price on Agile Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 9th. ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 3rd.
Large investors have recently added to or reduced their stakes in the stock. A.R.T. Advisors LLC boosted its holdings in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the period. Fosun International Ltd purchased a new position in Agile Therapeutics in the third quarter valued at $180,000. Finally, Renaissance Technologies LLC raised its stake in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after buying an additional 343,290 shares in the last quarter. Hedge funds and other institutional investors own 51.92% of the company’s stock.
NASDAQ:AGRX traded up $0.04 during midday trading on Monday, reaching $1.00. The company had a trading volume of 1,282,829 shares, compared to its average volume of 5,793,449. The firm has a market cap of $30.77 million, a PE ratio of -1.10 and a beta of -0.95. Agile Therapeutics has a 12-month low of $0.23 and a 12-month high of $5.33.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. Equities analysts anticipate that Agile Therapeutics will post -0.6 earnings per share for the current fiscal year.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Recommended Story: Trading Penny Stocks
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.